Insmed Incorporated (NASDAQ:INSM) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET

Company Participants

Bryan Dunn – Head of Investor Relations
Will Lewis – Chair and Chief Executive Officer
Sara Bonstein – Chief Financial Officer
Martina Flammer – Chief Medical Officer

Conference Call Participants

Joe Schwartz – Leerink Partners
Jessica Fye – JPMorgan
Nicole Germino – Truist Securities
Jason Zemansky – Bank of America
Jennifer Kim – Cantor
Jeff Hung – Morgan Stanley
Leon Wang – Barclays
Steve Willey – Stifel
Graig Suvannavejh – Mizuho

Operator

Thank you for standing by. My name is Jeannie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Insmed’s Third Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

I would now like to turn the conference over to Bryan Dunn, Head of Investor Relations. You may begin.

Bryan Dunn

Thank you, Jeannie. Good day, everyone, and welcome to today’s conference call to discuss Insmed’s third quarter 2024 financial results and provide a business update. I am joined today by Will Lewis, Chair and Chief Executive Officer; Sara Bonstein, Chief Financial Officer, who will each provide prepared remarks, after which they will be joined by Martina Flammer, Chief Medical Officer, for the Q&A session.

Before we start, please note that today’s call will include forward-looking statements based on our current expectations. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. Please refer to our filings with the Securities and Exchange Commission for more information concerning the risk factors that could affect the Company. The information we will discuss on today’s call is meant for the benefit of the investment community. It is not intended for promotional purposes and it is not sufficient for prescribing decisions.

I will now turn the call over to Will for prepared remarks.

Will Lewis

Thank you, Bryan, and welcome everyone. The announcement of the positive ASPEN data earlier this year marked the start of a new era for Insmed, one that will be defined by our ability to execute on the many opportunities we have in front of us. Our performance this quarter demonstrated the level of execution. That level of execution sets us up for this exciting new chapter of Insmed’s story. The opportunities before us are significant not only in terms of their potential impact on patients and our company, but also in terms of their sheer quantity. I’m proud to say that our team across the organization have continued to show a remarkable ability to deliver simultaneously on all of them.